TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $37.82 million. The enterprise value is $28.21 million.
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 39.55 million shares outstanding. The number of shares has increased by 24.74% in one year.
| Current Share Class | 39.55M |
| Shares Outstanding | 39.55M |
| Shares Change (YoY) | +24.74% |
| Shares Change (QoQ) | +62.22% |
| Owned by Insiders (%) | 7.94% |
| Owned by Institutions (%) | 35.38% |
| Float | 20.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.39 |
| Forward PS | 0.42 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.01, with a Debt / Equity ratio of 1.51.
| Current Ratio | 5.01 |
| Quick Ratio | 4.02 |
| Debt / Equity | 1.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.88 |
Financial Efficiency
Return on equity (ROE) is -159.87% and return on invested capital (ROIC) is -39.14%.
| Return on Equity (ROE) | -159.87% |
| Return on Assets (ROA) | -31.66% |
| Return on Invested Capital (ROIC) | -39.14% |
| Return on Capital Employed (ROCE) | -58.75% |
| Revenue Per Employee | $331,579 |
| Profits Per Employee | -$181,057 |
| Employee Count | 209 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 1.73 |
Taxes
| Income Tax | -144,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.07% in the last 52 weeks. The beta is 0.98, so TELA Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -81.07% |
| 50-Day Moving Average | 1.96 |
| 200-Day Moving Average | 2.82 |
| Relative Strength Index (RSI) | 25.75 |
| Average Volume (20 Days) | 516,826 |
Short Selling Information
The latest short interest is 694,080, so 1.75% of the outstanding shares have been sold short.
| Short Interest | 694,080 |
| Short Previous Month | 446,362 |
| Short % of Shares Out | 1.75% |
| Short % of Float | 3.38% |
| Short Ratio (days to cover) | 1.73 |
Income Statement
In the last 12 months, TELA Bio had revenue of $69.30 million and -$37.84 million in losses. Loss per share was -$1.33.
| Revenue | 69.30M |
| Gross Profit | 46.87M |
| Operating Income | -41.70M |
| Pretax Income | -40.30M |
| Net Income | -37.84M |
| EBITDA | -40.68M |
| EBIT | -41.70M |
| Loss Per Share | -$1.33 |
Full Income StatementBalance Sheet
The company has $52.67 million in cash and $43.06 million in debt, giving a net cash position of $9.61 million or $0.24 per share.
| Cash & Cash Equivalents | 52.67M |
| Total Debt | 43.06M |
| Net Cash | 9.61M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 28.46M |
| Book Value Per Share | 0.72 |
| Working Capital | 62.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.60 million and capital expenditures -$989,000, giving a free cash flow of -$42.58 million.
| Operating Cash Flow | -41.60M |
| Capital Expenditures | -989,000 |
| Free Cash Flow | -42.58M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
Gross margin is 67.63%, with operating and profit margins of -60.17% and -54.60%.
| Gross Margin | 67.63% |
| Operating Margin | -60.17% |
| Pretax Margin | -54.81% |
| Profit Margin | -54.60% |
| EBITDA Margin | -58.71% |
| EBIT Margin | -60.17% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.74% |
| Shareholder Yield | n/a |
| Earnings Yield | -100.06% |
| FCF Yield | -112.60% |
Analyst Forecast
The average price target for TELA Bio is $6.00, which is 537.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 537.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 25.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -4.51 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.51 |
| Piotroski F-Score | 2 |